Skip to content
  • Careers
  • Contact
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
  • Our Approach
    • ADC Landscape
    • IO Landscape
  • Clinical Programs
    • Clinical Trials
    • Active Programs
    • Pipeline
    • Scientific Publications
  • Investors
    • News releases
    • Events & presentations
    • Corporate governance
      • Governance Overview
      • Board of Directors
      • Management Team
      • Committee composition
    • Financial Information
      • SEC filings
    • Stock Information
      • Stock quote & chart
    • Analyst Coverage
    • SHAREHOLDER SERVICES
      • Investor FAQs
      • Email alerts
      • RSS feeds
Pyxis Oncology Logo
  • About
    • Overview
    • Leadership
  • Our Approach
    • ADC Landscape
    • IO Landscape
  • Clinical Programs
    • Clinical Trials
    • Active Programs
    • Pipeline
    • Scientific Publications
  • Investors
    • News releases
    • Events & presentations
    • Corporate governance
      • Governance Overview
      • Board of Directors
      • Management Team
      • Committee composition
    • Financial Information
      • SEC filings
    • Stock Information
      • Stock quote & chart
    • Analyst Coverage
    • SHAREHOLDER SERVICES
      • Investor FAQs
      • Email alerts
      • RSS feeds
  • Careers
  • Contact

Scientific publications

November 2017
A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma
SITC Poster
November 2017
A Pilot Study to Evaluate The Clinical and Immunological Effects of Incorporating a CD40-Agonistic Antibody into the Multimodality Treatment of Resectable Esophageal and GE Junction Cancersrcoma
SITC Poster
November 2017
Phase 1 Study to Evaluate the Safety and Tolerability of the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Poster
November 2017
First in Human Study with the CD40 Agonistic Monoclonal Antibody APX005M in Subjects with Solid Tumors
SITC Presentation

«34567
321 Harrison Avenue
11th Floor, Suite 1
Boston, MA 02118
(617) 453-3596 | info@pyxisoncology.com
Pyxis Oncology
X Logo Linkedin-in
  • Copyright © 2026 Pyxis Oncology
  • Privacy Policy
  • Accessibility
  • Expanded Access Policy